These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7870369)

  • 21. Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients.
    Ferraresso M; Ghio L; Edefonti A; Garavaglia R; Berardinelli L
    Pediatr Nephrol; 2002 Aug; 17(8):664-7. PubMed ID: 12185478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival.
    Campise M; Mikhail A; Quaschning T; Snyder J; Collins A
    Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii8-12. PubMed ID: 16079328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recombinant human erythropoietin and torasemide--innovations in nephrology].
    Internist (Berl); 1989 Mar; 30(3):220. PubMed ID: 2654065
    [No Abstract]   [Full Text] [Related]  

  • 24. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxalosis as a cause of absolute resistance to rHuEpo in chronic haemodialysis patients.
    Lorenzo V; Hernandez D; Dominguez M; Rodriguez A; Torres A
    Nephrol Dial Transplant; 1992; 7(11):1163-4. PubMed ID: 1336146
    [No Abstract]   [Full Text] [Related]  

  • 26. Implications of recombinant erythropoietin therapy for renal transplantation.
    Ward HJ
    Am J Nephrol; 1990; 10 Suppl 2():44-7; discussion 48-52. PubMed ID: 2260618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of protein-restricted diet and recombinant human erythropoietin in patients with chronic rejection of a transplanted kidney.
    Sanaka T; Takahashi K; Teraoka S; Toma H; Agishi T; Sugino N; Ota K
    Transplant Proc; 1992 Aug; 24(4):1571-2. PubMed ID: 1496661
    [No Abstract]   [Full Text] [Related]  

  • 28. Cyclosporine improves results in HLA-identical sibling renal transplants.
    Van Buren D; MacDonell R; Johnson HK; Richie R; Ynares C; Helderman JH; Green W; Crowe D
    Transplant Proc; 1994 Oct; 26(5):2514-5. PubMed ID: 7940772
    [No Abstract]   [Full Text] [Related]  

  • 29. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
    Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
    Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
    Bárány P; Pettersson E; Konarski-Svensson JK
    Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
    Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
    J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive early cyclosporine therapy is desirable in pediatric renal transplantation.
    al-Uzri A; Conley SB; Orlandi P; So S; Salvatierra O
    Transplant Proc; 1994 Feb; 26(1):88-90. PubMed ID: 8109036
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity.
    Grimm PC; Sinai-Trieman L; Sekiya NM; Robertson LS; Robinson BJ; Fine RN; Ettenger RB
    Kidney Int; 1990 Jul; 38(1):12-8. PubMed ID: 2385080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy.
    Scott-Douglas N; Zimmerman D; Klassen J
    Transplant Proc; 1996 Dec; 28(6):3165. PubMed ID: 8962226
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients.
    Altun B; Erdem Y; Haznedaroğlu I; Gürsoy M; Yasavul U; Turgan C; Cağlar S; Kirazli S
    Nephrol Dial Transplant; 1995 Nov; 10(11):2164. PubMed ID: 8643199
    [No Abstract]   [Full Text] [Related]  

  • 36. Prolonged renal allograft survival in chronic rejection by conversion to triple therapy.
    Beckingham IJ; Dennis MJ; Innes A; Burden RP; Morgan AG; Bishop MC
    Transplant Proc; 1993 Apr; 25(2):2100. PubMed ID: 8470283
    [No Abstract]   [Full Text] [Related]  

  • 37. Influence of renal mass on chronic kidney allograft rejection in rats.
    Heemann UW; Azuma H; Tullius SG; Mackenzie HS; Schmid C; Brenner BM; Tilney NL
    Transplant Proc; 1995 Feb; 27(1):549. PubMed ID: 7879094
    [No Abstract]   [Full Text] [Related]  

  • 38. Anemia, dialysis, and dollars.
    Klahr S
    N Engl J Med; 1996 Feb; 334(7):461-3. PubMed ID: 8552151
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of recombinant erythropoietin in a pregnant renal transplant recipient.
    Thorp M; Pulliam J
    Am J Nephrol; 1998; 18(5):448-51. PubMed ID: 9730574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The management of the failed renal allograft: an enigma with potential consequences.
    Langone AJ; Chuang P
    Semin Dial; 2005; 18(3):185-7. PubMed ID: 15934959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.